NCT03568422View on ClinicalTrials.gov

CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 5, 2019

Primary Completion Date

November 21, 2022

Study Completion Date

December 31, 2025

Conditions
Breast Cancer
Interventions
DRUG

CFI-402257

Orally taken on intermittent schedule (days 1, 2, 8, 9, 15 \& 16

DRUG

Paclitaxel

80 mg/m2 IV days 1, 8 \& 15 every 28 days

Trial Locations (4)

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

K7L 2V7

Kingston Health Sciences Centre, Kingston

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

M5G 2M9

University Health Network, Toronto

Sponsors
All Listed Sponsors
collaborator

Stand Up To Cancer

OTHER

collaborator

Canadian Breast Cancer Foundation

OTHER

collaborator

Ontario Institute for Cancer Research

OTHER

lead

Canadian Cancer Trials Group

NETWORK